1. Home
  2. CRI vs COLL Comparison

CRI vs COLL Comparison

Compare CRI & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRI
  • COLL
  • Stock Information
  • Founded
  • CRI 1865
  • COLL 2002
  • Country
  • CRI United States
  • COLL United States
  • Employees
  • CRI N/A
  • COLL N/A
  • Industry
  • CRI Apparel
  • COLL Biotechnology: Pharmaceutical Preparations
  • Sector
  • CRI Consumer Discretionary
  • COLL Health Care
  • Exchange
  • CRI Nasdaq
  • COLL Nasdaq
  • Market Cap
  • CRI 1.0B
  • COLL 958.8M
  • IPO Year
  • CRI 2003
  • COLL 2015
  • Fundamental
  • Price
  • CRI $31.75
  • COLL $35.62
  • Analyst Decision
  • CRI Sell
  • COLL Strong Buy
  • Analyst Count
  • CRI 4
  • COLL 4
  • Target Price
  • CRI $30.25
  • COLL $44.25
  • AVG Volume (30 Days)
  • CRI 1.3M
  • COLL 447.6K
  • Earning Date
  • CRI 10-24-2025
  • COLL 11-06-2025
  • Dividend Yield
  • CRI 10.13%
  • COLL N/A
  • EPS Growth
  • CRI N/A
  • COLL N/A
  • EPS
  • CRI 3.75
  • COLL 1.06
  • Revenue
  • CRI $2,833,315,000.00
  • COLL $707,007,000.00
  • Revenue This Year
  • CRI $0.84
  • COLL $22.23
  • Revenue Next Year
  • CRI N/A
  • COLL $2.78
  • P/E Ratio
  • CRI $8.42
  • COLL $32.98
  • Revenue Growth
  • CRI N/A
  • COLL 22.61
  • 52 Week Low
  • CRI $23.38
  • COLL $23.23
  • 52 Week High
  • CRI $71.99
  • COLL $42.29
  • Technical
  • Relative Strength Index (RSI)
  • CRI 70.76
  • COLL 43.81
  • Support Level
  • CRI $28.07
  • COLL $37.10
  • Resistance Level
  • CRI $29.06
  • COLL $39.12
  • Average True Range (ATR)
  • CRI 1.08
  • COLL 1.22
  • MACD
  • CRI 0.43
  • COLL -0.62
  • Stochastic Oscillator
  • CRI 98.01
  • COLL 17.95

About CRI Carter's Inc.

Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: